Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Edrophonium is a short and rapid-acting anticholinesterase drug classified as a cholinergic muscle stimulant. It acts by reversibly inhibiting the enzyme acetylcholinesterase, thereby increasing the concentration of acetylcholine at neuromuscular junctions. This prolongs stimulation of nicotinic and muscarinic receptors, resulting in enhanced muscle contraction. Edrophonium is primarily used as a diagnostic agent for myasthenia gravis (notably in the "Tensilon test") and to differentiate between myasthenic crisis and cholinergic crisis. It is also used to reverse non-depolarizing neuromuscular blockade after surgery or overdose with certain muscle relaxants such as curare derivatives. The onset of action occurs within 30–60 seconds after injection, with effects lasting about 10–30 minutes[1][4][6]. Due to its brief duration, it is not suitable for maintenance therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on edrophonium.